Live·Verified funding discovery · 2026.2
874 grants · 19 open · 435 companies · 2640 concepts874 / 19 / 435 / 2640
COMPANIESCompanies rated · 435 (no change)PROJECTSProjects rated · 70 (no change)CATALOGUE874 grants in catalogue · 19 open right nowPOWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CACOMPANIESCompanies rated · 435 (no change)PROJECTSProjects rated · 70 (no change)CATALOGUE874 grants in catalogue · 19 open right nowPOWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
← Back to Eternal Search

Kumar Gondi

individual
Ecosystem influencer

About

Kumar Gondi, PhD, is a biopharma R&D executive and scientific advisor focused on nonclinical development, drug metabolism and pharmacokinetics, toxicology, and translational drug discovery. General Proximity says he most recently served as Senior Vice President of Nonclinical R&D at Bristol Myers Squibb, after earlier leadership roles at Celgene, Abbott, and Amgen. He is also a published scientist and co-inventor on drug-development programs including Kaletra, with recent work connected to cereblon biology and targeted protein degradation.

Areas of interest

biotechdrug discoverydrug metabolismpharmacokineticstoxicologynonclinical developmentmedicinal chemistrytargeted protein degradationcereblon biologysmall moleculesbiotherapeuticscell therapies